Research progress of neuraminidase inhibitors for anti-influenza.
- Author:
Ai-Lin LIU
1
;
Hai-Di WANG
;
Fan YANG
;
Guan-Hua DU
Author Information
1. Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- Publication Type:Journal Article
- MeSH:
Antiviral Agents;
pharmacology;
therapeutic use;
Drug Resistance, Viral;
drug effects;
Enzyme Inhibitors;
pharmacology;
therapeutic use;
Humans;
Influenza, Human;
drug therapy;
prevention & control;
virology;
Neuraminidase;
antagonists & inhibitors;
Oseltamivir;
pharmacology;
therapeutic use;
Zanamivir;
pharmacology;
therapeutic use
- From:
Acta Pharmaceutica Sinica
2009;44(9):935-942
- CountryChina
- Language:Chinese
-
Abstract:
Influenza is a global contagious disease, which causes hundreds of thousands of people deaths. And new subtype of influenza may cause pandemic influenza, and lead to more serious consequence. Drugs for anti-influenza have played very important roles in influenza treatment and prevention, especially neuraminidase inhibitors are effective on both influenza A and B which have more safety and tolerance, therefore they have been widely used for influenza treatment. However, several viral drug-resistant cases have been reported. In this paper, the clinic therapy, prevention and drug resistance of neuraminidase inhibitors, including zanamivir, oseltamivir and peramivir, and progress in the research and development in our country are presented in order to promote research and development of new drugs for influenza treatment and prevention.
